1-3 of 3
Benjamin Suttle
Close
Sort by
Journal Articles

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Clementine Sarkozy, MD, Franck Morschhauser, MD, Jean-Marie Michot, MD, Benjamin Suttle, Lionel Karlin, MD, Steven LE Gouill, MD PhD, Fabrice Jardin, MD PhD, Herve Tilly, MD, Charles Herbaux, MD, Gilles Andre Salles, Vincent Ribrag, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4191.
https://doi.org/10.1182/blood-2018-99-113193
Published: 2018
Journal Articles

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Clinical Trials & Observations
Eytan M. Stein, Guillermo Garcia-Manero, David A. Rizzieri, Raoul Tibes, Jesus G. Berdeja, Michael R. Savona, Mojca Jongen-Lavrenic, Jessica K. Altman, Blythe Thomson, Stephen J. Blakemore, Scott R. Daigle, Nigel J. Waters, A. Benjamin Suttle, Alicia Clawson, Roy Pollock, Andrei Krivtsov, Scott A. Armstrong, Jorge DiMartino, Eric Hedrick, Bob Löwenberg, Martin S. Tallman
Journal: Blood
Blood (2018) 131 (24): 2661–2669.
https://doi.org/10.1182/blood-2017-12-818948
Published: 2018
Includes: Supplemental data
Journal Articles

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)

H. Miles Prince, Dirk Hönemann, Andrew Spencer, David A. Rizzieri, Edward A. Stadtmauer, Andrew W. Roberts, Nizar Bahlis, Guido Tricot, Bill Bell, Douglas J. DeMarini, A. Benjamin Suttle, Katherine L. Baker, Lini N. Pandite
Journal: Blood
Blood (2009) 113 (19): 4819–4820.
https://doi.org/10.1182/blood-2009-02-207209
Published: 2009